28th Annual Meeting May 13-17, 2025 New Orleans Booth #1057 Book Appointments with Our Team: https://calendly.com/jacqueline-keller-neurochase/neurochase-meeting-asgct
Pharmaceutical and medical device industry veteran Jacqueline Keller joins Neurochase as the company prepares to bring its pioneering CED drug delivery device for CNS indications to market – Neurochase has…
VIVOLTA partners with Neurochase to manufacture electrospun micro-catheters delivering advanced CNS therapies to the brain Waalre, The Netherlands, 13 November 2024 – VIVOLTA, the medical electrospinning solutions provider, has signed a long-term partnership…
Original Article: Global News Wire Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders PHILADELPHIA, Jan. 27, 2023 (GLOBE NEWSWIRE) — Spark…
Innervate Therapeutics is a biotechnology company focused on developing glial cell -derived neurotrophic factor (GDNF) gene therapies to achieve neuro-restoration and neuroprotection in diseases including PD and MND. GDNF, a…
Original Article Today, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading expert in the area of neurosurgery, to develop novel…
AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB)…
CombiGene’s and Neurochase’s preclinical study provides valuable information for the upcoming long-term studies in toxicology and biodistribution STOCKHOLM — On June 28, 2021, CombiGene (“CombiGene”, “the Company”) announced that the…
As gene therapy pioneers begin to tackle systemic diseases and those with a large patient cohort, their focus must increasingly be set on the twin goals of exceptional AAV yields…
